Clinical Trial Update: Tumour Necrosis Factor Release in Locally Advanced Breast Cancer Patients Receiving Neoadjuvant Docetaxel [Phase 1]

View source ↗

Summary

A Phase 1 trial investigating tumor necrosis factor release in locally advanced breast cancer patients receiving neoadjuvant docetaxel has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Conditions: Breast Cancer | Phase 1 | Status: WITHDRAWN